| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8247395 | GALDERMA LABS LP | Topical skin care composition |
Oct, 2022
(1 year, 6 months ago) | |
| US8653053 | GALDERMA LABS LP | Topical skin care composition |
Oct, 2022
(1 year, 6 months ago) | |
| US7939516 | GALDERMA LABS LP | Topical skin care composition |
May, 2025
(11 months from now) | |
| US7915243 | GALDERMA LABS LP | Topical skin care composition |
Mar, 2026
(1 year, 10 months from now) | |
Tri-Luma is owned by Galderma Labs Lp.
Tri-Luma contains Fluocinolone Acetonide; Hydroquinone; Tretinoin.
Tri-Luma has a total of 4 drug patents out of which 2 drug patents have expired.
Expired drug patents of Tri-Luma are:
- US8247395
- US8653053
Tri-Luma was authorised for market use on 18 January, 2002.
Tri-Luma is available in cream;topical dosage forms.
The generics of Tri-Luma are possible to be released after 22 March, 2026.
Drugs and Companies using FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN ingredient
Market Authorisation Date: 18 January, 2002
Treatment: NA
Dosage: CREAM;TOPICAL
More Information on Dosage
TRI-LUMA family patents
